Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Post-menopausal women (defined as having had no menstrual period for 12 months, or having had both ovaries and fallopian tubes surgically removed) who have hormone receptor positive breast cancer, a pre-cancerous breast condition called ductal carcinoma in situ (DCIS), or other conditions that put them at high risk for breast cancer
- Women in the above group who are planning to start, or have started within the last 6 months, a type of hormone-blocking medication called an aromatase inhibitor, following a consultation at a breast clinic or cancer centre (up to 25 women in this group)
- Women in the above group who are planning to start a hormone-blocking medication called Tamoxifen (up to 25 women in this group)
- Healthy post-menopausal women with none of the above breast conditions (up to 25 women in this group)
Who may not be able to join:
- People who have been diagnosed with diabetes
- People who are currently taking medications that could affect how the body processes blood sugar
- People whose fasting blood sugar level or average blood sugar measure (HbA1c) is above a certain threshold at screening (confirm with trial site for exact values)
- People who have had surgery on the upper part of the digestive system that affects how the stomach empties or absorbs food — for example, weight-loss (bariatric) surgery or a procedure called fundoplication
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Kalpana Muthusamy, MBBS, MD, Mayo Clinic in Rochester
Phone: 855-776-0015
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Disposition Index (DI); Glucose homeostasis - tamoxifen compared to no treatment; Glucose homeostasis - aromatase inhibitor compared to tamoxifen
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.